ERIS
Eris Lifesciences
Each stock's 10,000-path forecast, rendered as light.
Eris Lifesciences (ERIS) Stock Analysis & Case Study
Is ERIS a good buy? The data-driven verdict.
Eris Lifesciences (ERIS) trades at ₹1,437,on the numbers it worth a closer look, a Downstox Snapshot Score of 62/100.
On the numbers, Eris Lifesciences (ERIS) worth a closer look, a Downstox Snapshot Score of 62/100, weighing premium at 31.6× earnings, ROE of 18.7%, a 63% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
ERIS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is ERIS overvalued? ERIS P/E vs its sector
ERIS's P/E of 31.6× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.51% dividend yield is below the peer median of 1.65%.
ERIS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of ERIS history (17%/yr drift, 33%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ERIS 2027 | ₹1,056 | ₹1,618 | ₹2,490 | +12% |
| ERIS 2028 | ₹1,001 | ₹1,816 | ₹3,313 | +25% |
| ERIS 2029 | ₹983 | ₹2,067 | ₹4,179 | +43% |
| ERIS 2030 | ₹974 | ₹2,306 | ₹5,313 | +59% |
| ERIS 2031 | ₹996 | ₹2,593 | ₹6,683 | +79% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ERIS goes up, or doubles?
The bull case for ERIS
- High return on equity (18.7%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- A 10,000-path probability model puts a 63% chance the price is higher in a year, with a median target of ₹1,618 (+12%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹4,179.
The bear case & risks
- At 31.6× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹983.
ERIS volatility & expected range, how bumpy is the ride?
Over the last 2.0 years ERIS compounded at 17%/year with annualized volatility of 33%. That volatility implies a 1-year 80% range of ₹1,056–₹2,490, the honest backbone behind any single price target.
ERIS price forecast, the full 60-month probability fan
ERIS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ERIS hits common targets within the simulated horizon?
Full multi-horizon detail on the ERIS price target & forecast page.
ERIS Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. ERIS scores 4/9,mixed financial health.
ERIS MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy ERIS with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 30.5% | 3.3× |
| ZerodhaCHEAPEST | 30.5% | 3.3× |
| DhanCHEAPEST | 30.5% | 3.3× |
Compare every broker on the ERIS MTF page.
ERIS vs peers,sector comparison
About Eris Lifesciences: sector, index & market-cap context
Eris Lifesciences (ERIS) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹19,939 Cr. See more Nifty 200 stocks.
How the ERIS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Eris Lifesciences's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ERIS analysis, FAQs
Is Eris Lifesciences (ERIS) a good buy?
On the numbers, Eris Lifesciences (ERIS) worth a closer look, a Downstox Snapshot Score of 62/100, weighing premium at 31.6× earnings, ROE of 18.7%, a 63% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ERIS overvalued or undervalued?
ERIS trades at 31.6× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the ERIS share price target for 2031?
ERIS's probability-weighted 2031 median target is ₹2,593, with an 80% range of ₹996–₹6,683 (10,000-path Monte-Carlo).
What is the probability ERIS doubles in 5 years?
The modelled probability of ERIS reaching ₹2,897 (2×) within 5 years is 44%.
What is the bull case for ERIS?
High return on equity (18.7%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. A 10,000-path probability model puts a 63% chance the price is higher in a year, with a median target of ₹1,618 (+12%).
What are the risks in ERIS?
At 31.6× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.